Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2018-10-10 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于有关媒体报道的说明
Regulatory Filings Classification · 95% confidence The document is a company announcement addressing media reports and clarifying issues related to patent disputes, team changes, and company performance. It includes references to previous litigation disclosures and company information disclosure obligations. The document does not contain financial statements, detailed financial analysis, or formal report data. It is a regulatory announcement clarifying information rather than a financial report or earnings release. The length is short (1838 characters), and it serves as a public statement to investors and the market. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and clarification.
2018-10-10 Chinese
股东股份减持的进展公告
Major Shareholding Notification Classification · 95% confidence The document is a shareholder announcement regarding the progress of a shareholding reduction by a major shareholder, BETA PHARMA, INC. It details the number of shares reduced, the reduction period, prices, and compliance with relevant regulations. It does not contain financial statements or performance data, nor is it a report or presentation. It is an official announcement about a shareholder's transaction in the company's shares, specifically a reduction in shareholding. This fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, confirming it is not a full report or earnings release.
2018-09-27 Chinese
股东股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the pledge of shares by a shareholder of the company. It details the number of shares pledged, the pledge start and end dates, the pledgee, and the proportion of shares pledged. There is no financial report, earnings data, or management discussion. The content fits the category of a capital or financing update related to changes in the company's capital structure (share pledges). The document length is short and it is not an announcement of a report publication but a direct disclosure of a financing-related event.
2018-08-31 Chinese
股东股份质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement from a company disclosing details about the pledge of shares by its shareholders. It includes specific data on the number of shares pledged, pledge dates, pledgees, and the proportion of shares pledged relative to total holdings. The document is short (1130 characters) and focuses solely on share pledge information without any financial statements, management discussion, or regulatory certifications. It is not an annual or interim report, nor an earnings release or management report. It is also not a director's dealing report since it concerns shareholders pledging shares, not insider transactions. The content fits the description of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership or related shareholding activities such as pledges. Therefore, the appropriate classification is MRQ with high confidence.
2018-08-24 Chinese
2018年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2018 年半年度报告全文' which translates to '2018 Semi-Annual Report Full Text'. It contains detailed sections including company overview, financial data, business summary, management discussion and analysis, and financial statements. The report period is specified as January 1, 2018 to June 30, 2018, indicating it is a report for a period shorter than a full fiscal year. The content includes comprehensive financial data, operational analysis, and management commentary typical of an interim or quarterly report. The length of the document (15,000 characters) and the presence of substantive financial and operational information confirm it is the actual report, not just an announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2018
2018-08-23 Chinese
中国国际金融股份有限公司关于公司2018年上半年度跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2018年上半年度跟踪报告" (2018 First Half Year Follow-up Report) by the sponsor China International Capital Corporation Limited regarding Beta Pharma Co., Ltd. It details the sponsor's review and supervision activities, company governance, compliance with commitments, and other oversight matters during the first half of 2018. The content includes detailed monitoring and compliance information rather than just an announcement or summary. The document length is about 4995 characters, which is sufficient to contain substantive content. The document is a follow-up report for a half-year period, which aligns with an Interim / Quarterly Report (IR) classification, as it contains substantive financial and compliance oversight information for a period shorter than a full fiscal year. It is not a simple announcement or certification, nor a full annual report. Therefore, the best fit is Interim / Quarterly Report (IR). H1 2018
2018-08-23 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.